CH672987A5 - - Google Patents

Download PDF

Info

Publication number
CH672987A5
CH672987A5 CH2611/87A CH261187A CH672987A5 CH 672987 A5 CH672987 A5 CH 672987A5 CH 2611/87 A CH2611/87 A CH 2611/87A CH 261187 A CH261187 A CH 261187A CH 672987 A5 CH672987 A5 CH 672987A5
Authority
CH
Switzerland
Prior art keywords
bromocriptine
disease
therapy
day
test
Prior art date
Application number
CH2611/87A
Other languages
German (de)
English (en)
Inventor
Douglas Dr Larson
Peter Hiestand
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CH672987A5 publication Critical patent/CH672987A5/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH2611/87A 1986-07-14 1987-07-09 CH672987A5 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88511086A 1986-07-14 1986-07-14

Publications (1)

Publication Number Publication Date
CH672987A5 true CH672987A5 (xx) 1990-01-31

Family

ID=25386156

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2611/87A CH672987A5 (xx) 1986-07-14 1987-07-09

Country Status (13)

Country Link
JP (1) JPS6323817A (xx)
KR (1) KR880001292A (xx)
AU (1) AU602154B2 (xx)
CH (1) CH672987A5 (xx)
DE (1) DE3722383A1 (xx)
DK (1) DK363887A (xx)
FR (1) FR2601245A1 (xx)
GB (1) GB2192541B (xx)
IT (1) IT1224222B (xx)
NL (1) NL8701631A (xx)
PH (1) PH24525A (xx)
SE (1) SE8702843L (xx)
ZA (1) ZA875145B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3814521A1 (de) * 1987-05-07 1988-11-17 Sandoz Ag Neue anwendung von dopaminrezeptor-agonisten
EP0327040A3 (de) * 1988-02-05 1990-11-28 Predrag Dr.Sc. Sikiric Verwendung von Dopamin und/oder von Dopamin-Agonisten zur Herstellung eines Arzneimittels für die Behandlung des Verdauungstrakts
US6004972A (en) * 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5344832A (en) * 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5731287A (en) * 1988-05-10 1998-03-24 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5700800A (en) * 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5585347A (en) * 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US5744477A (en) * 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5468755A (en) * 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5668155A (en) * 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5830895A (en) * 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
CA2030174C (en) * 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
AU3419293A (en) * 1991-12-23 1993-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The A therapeutic process for the treatment of the pathologies of type II diabetes
US5696128A (en) * 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) * 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
US5626860A (en) * 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
EP2091537B1 (de) 2006-11-23 2013-05-22 Sinoxa Pharma GmbH Pharmazeutische zusammensetzungen zur behandlung von kapillarer arteriopathie
AU2017254650A1 (en) * 2016-04-20 2018-11-15 Veroscience Llc Composition and method for treating metabolic disorders
JP7231255B2 (ja) 2017-10-18 2023-03-01 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 改善されたブロモクリプチン製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
CH666406A5 (de) * 1984-02-29 1988-07-29 Sandoz Ag Verfahren zur herstellung von mikrokapseln, welche bromokriptinmesylat als pharmakologischen wirkstoff enthalten.
GB2154874B (en) * 1984-02-29 1987-11-04 Sandoz Ltd Bromoscriptine compositions

Also Published As

Publication number Publication date
GB2192541A (en) 1988-01-20
DK363887A (da) 1988-01-15
NL8701631A (nl) 1988-02-01
DE3722383A1 (de) 1988-01-28
JPS6323817A (ja) 1988-02-01
GB2192541B (en) 1990-05-02
ZA875145B (en) 1989-02-22
AU602154B2 (en) 1990-10-04
IT8748160A0 (it) 1987-07-10
IT1224222B (it) 1990-09-26
FR2601245A1 (fr) 1988-01-15
AU7558787A (en) 1988-01-21
DK363887D0 (da) 1987-07-13
GB8716323D0 (en) 1987-08-19
KR880001292A (ko) 1988-04-22
SE8702843L (sv) 1988-01-15
PH24525A (en) 1990-07-18
SE8702843D0 (sv) 1987-07-13

Similar Documents

Publication Publication Date Title
CH672987A5 (xx)
DE69211406T2 (de) Verwendung von Rapamycin zur Behandlung des Diabetes
DE69224080T2 (de) Verwendung von nsaid zur behandlung von demenz
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE68924372T2 (de) Behandlung von diabetes mellitus typ 2.
DE69131386T2 (de) Verwendung von L-Deprenyl zur Hemmung des Alterniedergangs des Immunsystems in Säugetieren
DE3234947A1 (de) Arzneimittel zur behandlung von immundefektzustaenden
DE3526545A1 (de) Neue pharmazeutische anwendung von (nva)(pfeil hoch)2(pfeil hoch)- und dihydro-(val)(pfeil hoch)2(pfeil hoch)-cyclosporin
DE3247062A1 (de) Verwendung eines chelatbildners als arzneimittel zur behandlung der alzheimer-krankheit
DE3338995A1 (de) Bilobalid enthaltende arzneimittel
DE69424362T2 (de) Verwendung von Histamin-gamma-globulin zur Herstellung eines immunomodulierenden und antiinflammatorischen Agens
EP0474712B1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen
DE69925488T2 (de) Verwendung von fk506 und verwandten makroliden zur herstellung eines medikaments für die behandlung und vorbeugung von schmerzen
DE3590035T1 (de) Diphenhydramin enthaltende, analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
CH666188A5 (de) Immuno-regulator in form einer pharmazeutischen zusammensetzung.
DE69323759T2 (de) Verwendung von toremifene für die behandlung von sle
EP0236390B1 (de) Mittel gegen multiple sklerose
DE3750235T2 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
WO2002038150A1 (de) Aktivatoren von peroxisom-proliferator-aktivierten rezeptoren alpha, beta als arzneimittel zur behandlung von immunologisch bedingten hautstörungen
DE4136215A1 (de) Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
DE3916417C2 (xx)
DE69423806T2 (de) Therapeutisches Agens für NIDDM
DE60206280T2 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
Kennedy et al. Spinal changes in the neuropathy of thallium poisoning: a case with neuropathological studies
DE2660486C2 (de) Verwendung von 2-Hydroxymethyl-3,4,5-trihydroxypiperidin als Arzneimittel

Legal Events

Date Code Title Description
PL Patent ceased